6 results
Outpatient Treatment of with Community-Acquired Pneumonia (CAP)
No comorbidities or risk factors for MRSA or Pseudomonas aeruginosa:
Outpatient Treatment ... fluoroquinolone #IDSA ... #Outpatient #CAP ... Acquired #Pneumonia #Antibiotics ... Management #Guidelines #pharmacology
IDSA Recommendations for Preventing and Treating HHV-8 Diseases—Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL), Multicentric Castleman’s
IDSA Recommendations ... recommended for KS treatment ... IV ganciclovir can ... #Prevention #Treatment ... infections #HIVAIDS #pharmacology
Macrolides - Erythromycin, Clarithromycin, Azithromycin - Antibiotics Class Overview

50S Ribosomal Inhibitor (PO and IV)
Spectrum: Atypical organisms
Class Overview ... Strep throat in PCN ... Ceftriaxone for CAP ... Used for MAC treatment ... #Pharmacology #Antibiotics
Cauda Equina Syndrome Overview

Cauda Equina Syndrome:
 • Prevalence: 1:33,000-100,000 ppl/yr
 • Incidence: 1.5-3.4 million ppl/yr
 •
Equina Syndrome Overview ... constipation Differential ... • CBC, ESR, CRP ... axial T1 and T2 Treatment ... Equina #syndrome #differential
IDSA Recommendations for Prevention and Treatment of Pneumocystis Pneumonia (PCP) in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
IDSA Recommendations ... for Prevention ... and Treatment of ... #Prevention #Treatment ... HIVAIDS #management #pharmacology
Anti-Pseudomonal - Antibiotics Class Overview

Pseudomonas aeruginosa is a non-fermenting Gram-negative bacillus that inhabits a variety of
Class Overview ... so use only if PCN-allergic ... empiric Pseudomonas treatment ... Polymyxin B(IV) #Pharmacology ... #Overview #AntiPseudomonal